Nova Rad Vax 907 is produced based on the viruses currently circulating in Iran and the Middle East region and shows the highest antigenic similarity to the pathogenic viruses prevalent in this area. This product contains a minimum of 10 log₂HAU of inactivated Newcastle disease virus (strain G7) and 9 log₂HAU of inactivated avian influenza virus subtype H9N2. It is capable of inducing appropriate antibody responses against Newcastle disease and avian influenza viruses following vaccination and providing active immunity against Newcastle disease and Type A avian influenza subtype H9N2.
Nova Rad Vax 907 is formulated with an oil‑based adjuvant, acts as a strong inducer of antibody production and is stable, low‑viscosity, and easy to administer.